ストックスクリーナーアプリを入手
41.01
0.34%
0.14
アフターアワーズ：
40.81
-0.20
-0.49%
Moderna Inc (MRNA) 最新ニュース
A Double Blow for Moderna – Seqirus Topples Two mRNA Patent Applications - Pearce IP
1 Stock to Buy, 1 Stock to Sell This Week: Cisco, Moderna - Investing.com Nigeria
United StatesGoodwin Advises Moderna On Strategic Collaboration With Recordati To Globally Commercialize Investigational Propionic Acidemia Therapeutic (MRNA-3927) For $50 Million Upfront And Up To $110 Million In - Mondaq
Mixed Options Sentiment as Moderna (MRNA) Sees Slight Decline - GuruFocus
Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Moderna faces $5 billion mRNA patent lawsuit after ‘Star Trek’ ruling - thestreet.com
Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock - Yahoo Finance
Moderna (MRNA) to Release Quarterly Earnings on Friday - MarketBeat
Morgan Lewis Hires Moderna In-House Pro In Munich - Law360
Defiance adds single stock ETFs tied to Zeta Global, Moderna - Structured Retail Products
Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? - Finviz
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up - GlobeNewswire
Judge Wolson Issues Key Summary Judgment Ruling on the Eve of Trial in the Arbutus v. Moderna mRNA Vaccine and Lipid Nanoparticle Case - JD Supra
The Escalator: Moderna, Sparrow Pharmaceuticals, Takeda and more - Medical Marketing and Media
Analysts Offer Insights on Healthcare Companies: Merck KGaA (GB:0O14) and Moderna (MRNA) - The Globe and Mail
Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider - GlobeNewswire Inc.
Moderna Inc (MRNA) Stock Price, Trades & News - GuruFocus
Judge Wolson Issues Key Summary Judgment Ruling on Eve of Trial in Arbutus v. Moderna - IPWatchdog.com
Jim Cramer on Moderna: "Even Though the Stock's on the Mend, There Are Many Pharma and Biotech Names That I Like Better" - Finviz
Jim Cramer on Moderna: “Even Though the Stock’s on the Mend, There Are Many Pharma and Biotech Names That I Like Better” - Insider Monkey
Moderna CEO hails breakthrough mRNA cancer vaccine that halves melanoma recurrence risk with Keytruda - Fox Business
Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc. - Investing News Network
PATENT—D. Del.: Most COVID-19... - VitalLaw.com
Moderna's 7-Step Guide to Veeva AI for PromoMats - Veeva
Why The Narrative Around Moderna (MRNA) Is Shifting After Mixed Analyst Updates - Yahoo Finance
Moderna Refocuses On Rare Disease Pipeline As Leadership Evolves - Yahoo Finance
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Are Wall Street Analysts Bullish on Moderna Stock? - Barchart.com
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - Shreveport Times
How Moderna Uses Decision Intelligence to Enable an Autonomous Cold Chain, Upcoming Webinar Hosted by Xtalks - Yahoo Finance
BioNTech Expands Beyond mRNA While Moderna Focuses on mRNA Pipeline Post-Pandemic - geneonline.com
'Star Trek'-Citing Judge Says Moderna Can't Ax $5B Vax IP Suit - Law360
Moderna Again Fails to Shift Most Covid-Shot Patent Costs to US - Bloomberg Law News
Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Moderna (MRNA) Sees Moderate Bearish Activity Amid Upcoming Earnings - GuruFocus
Patent Ruling Update Affects Arbutus Biopharma (ABUS) in Legal B - GuruFocus
Arbutus Biopharma (ABUS) Patent Dispute Over COVID-19 Vaccine De - GuruFocus
Arbutus jumps on ruling in patent dispute with Moderna (ABUS:NASDAQ) - Seeking Alpha
Jim Cramer on Moderna: “We have to wait and see” - MSN
Spotlight on Moderna: Analyzing the Surge in Options Activity - Benzinga
Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 43% - simplywall.st
Moderna Refocuses On Rare Diseases As New Leadership Shapes Pipeline - Yahoo Finance
Is Moderna (MRNA) Pricing Fair After Recent 42.8% Monthly Share Price Jump - Yahoo Finance
Gainers Report: Can Moderna Inc continue delivering strong returnsIndex Update & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Moderna Stock Slips As Ambitious Cancer Trials Drag On - TipRanks
91,010 Shares in Moderna, Inc. $MRNA Purchased by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Privium Fund Management B.V. Lowers Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna appoints David Berman as new chief development officer By Investing.com - Investing.com South Africa
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates - Treasure Coast News
Moderna: Analyzing The January Rally And The Road Ahead (Rating Upgrade) (NASDAQ:MRNA) - Seeking Alpha
Moderna (MRNA) Announces Leadership Changes Amid Strategic Shift - GuruFocus
Moderna CMO Jacqueline Miller to step down - WKZO
Moderna announces departure of medical chief (MRNA:NASDAQ) - Seeking Alpha
Leerink Partners Adjusts Moderna Price Target to $17 From $18, Maintains Underperform Rating - marketscreener.com
Moderna, Inc. Announces Executive and Committee Changes, Effective March 2, 2026 - marketscreener.com
Dr. David Berman to Join Moderna as Chief Development Officer - The Progress Index
Moderna Vs. Novavax: 2 Pandemic Vaccine PioneersWhich Offers Better Value Today? (MRNA) - Seeking Alpha
0.23%
1.25%
大文字化:
|
ボリューム (24 時間):